Navigation Links
New Data Analyses from Lorcaserin Phase 3 Clinical Trials to be Presented at Obesity 2011
Date:9/26/2011

of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from Arena's expectations. Factors that could cause actual results to differ materially from the forward-looking statements include, but are not limited to, the following: the timing of regulatory review and approval is uncertain; the risk that data and other information related to Arena's research and development programs may not meet safety or efficacy requirements or otherwise be sufficient for regulatory approval; Arena's response to the CRL for the lorcaserin NDA or submission of a Marketing Authorization Application for regulatory approval of lorcaserin may not be submitted when anticipated, if at all; the FDA may request other information prior to or after Arena submits such response or approval of the lorcaserin NDA; unexpected or unfavorable new data; risks related to commercializing new products; Arena's ability to obtain and defend its patents; the timing, success and cost of Arena's research and development programs; results of clinical trials and other studies are subject to different interpretations and may not be predictive of future results; clinical trials and other studies may not proceed at the time or in the manner expected or at all; Arena's ability to obtain adequate funds; risks related to relying on collaborative agreements; the timing and receipt of payments and fees, if any, from collaborators; and satisfactory resolution of pending and any future litigation or other disagreements with others. Additional factors that could cause actual results to differ materially from those stated or implied by Arena's forward-looking statements are disclosed in Arena's filings with the Securities and Exchange Commission. These forward-looking statements represent Arena's judgment as of the time of this release. Arena disclaims any intent or obligation to update these forward-looking statements, other than as may be required under applicable law.Contact
'/>"/>
SOURCE Arena Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Four Analyses of Three-Year Clinical Data Suggest CYPHER(R) Sirolimus-Eluting Coronary Stent May Provide Alternative to Surgery for Patients with Multivessel Disease
2. Xeloda XeNA Study Analyses of Xeloda, Docetaxel and Herceptin Combination Therapy for Metastatic Breast Cancer Featured at Major New Breast Cancer Symposium
3. Xeloda(R) XeNA Study Analyses of Xeloda, Docetaxel and Herceptin Combination Therapy for Metastatic Breast Cancer Featured at Major New Breast Cancer Symposium
4. Interim Response and Safety Analyses Support Continuation of Allos Therapeutics Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-Cell Lymphoma
5. New Analyses of Long-Term LIALDA(TM) (mesalamine) Data Presented at ACG
6. New MIRCERA(R) Data Analyses to be Featured at the American Society of Nephrology Annual Meeting
7. New Analyses Presented at ASCO Reaffirmed Efficacy and Safety of TORISEL in Patients With Advanced Kidney Cancer
8. Preliminary Analyses from Phase 2 Genzyme Study Highlight Efficacy and Safety of Clofarabine in Older Adult AML Patients
9. Independent Analyses of the SEAS, SHARP and IMPROVE-IT Studies of Ezetimibe
10. New Analyses Indicate that Divigel(R) (estradiol gel) 0.1% Is a Valuable Option for Certain Postmenopausal Women With Hot Flashes
11. Results and Additional Analyses From Efficacy and Safety Study of Cortheras Relaxin in Acute Heart Failure to be Presented at Heart Failure Congress 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... BOSTON , Jan. 15, 2014 Tegra Medical is ... Mark King as its new Chief Executive Officer.  Mark ... in which he has overseen the company,s four facilities in ... and Costa Rica.  Mr. King joined Tegra Medical in 2012 ...
(Date:1/15/2014)... 15, 2014 The Cadence Fitness & Health Center ... the Medical Fitness Association, a non-profit organization assisting medically ... potential. The Cadence Fitness & Health Center is the ... second in the Chicagoland area. "The certification ...
(Date:1/15/2014)... 15, 2014 Reportlinker.com announces that a ... its catalogue: PharmaPoint: ... Market Analysis to 2022 ... - India Drug Forecast and Market Analysis ...
Breaking Medicine Technology:Tegra Medical Appoints New Chief Executive Officer 2Tegra Medical Appoints New Chief Executive Officer 3Cadence Fitness & Health Center Certified as Medical Fitness Facility 2Cadence Fitness & Health Center Certified as Medical Fitness Facility 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5
... Hill-Rom Holdings, Inc., (NYSE: HRC ) ... the Credit Suisse,s 2011 Healthcare Conference in Phoenix on ... You are invited to listen to the live discussion ... access it directly at http://cc.talkpoint.com/cred001/110911a_ah/?entity=1_CIKQF3F .  A recorded ...
... 2011 Seven Summits Research issues critical PriceWatch Alerts for ... what our analysts have discovered about these stocks read the ... (Note: You may have to copy this link into your ... Alerts cover the following stocks: Intel Corporation (Nasdaq: ...
Cached Medicine Technology:Critical Alerts For Intel, Mosaic, Deckers, Foot Locker, and Jazz Pharmaceuticals Released By Seven Summits Research 2
(Date:7/10/2014)... (PRWEB) July 10, 2014 Thousands ... gather in Copenhagen this July 13-17 to reveal ... the world closer to breakthroughs in dementia science. ... world’s largest conference of its kind. , As ... serves as a catalyst for generating new knowledge ...
(Date:7/10/2014)... York, US (PRWEB) July 10, 2014 ... , Merrill DataSite recently streamed the live webinar ‘Capitalizing ... a discussion from a group of several M&A experts ... seeing in the broader energy transaction marketplace. These experts ... and how the deal market in this sector has ...
(Date:7/10/2014)... CBPartners, a global leader in consulting ... new website. The redesigned site boasts improved navigation ... the firm’s thought pieces, blog posts, and conference presentations. ... showcase our insights, capabilities, and to provide timely updates ... Officer, Cyrus Chowdhury. “An enhanced online presence is ...
(Date:7/10/2014)... Best Drug Rehabilitation , ... family close by during a stay in rehab ... not the process is successful, has launched an ... http://www.bestdrugrehabilitation.com/success-stories/ . , The new Success Stories ... several Best Drug Rehabilitation graduates who wanted to ...
(Date:7/10/2014)... Washington, New York (PRWEB) July 10, 2014 ... firm dedicated to protecting the rights of victims ... couple has brought a lawsuit over allegations that ... her body by a power morcellator used during ... has been filed against Richard Wolf Medical Instruments ...
Breaking Medicine News(10 mins):Health News:Register to Download Merrill DataSite's Report: Capitalizing on the Shifting Sands of the Energy Market 2Health News:CBPartners Announces New Website 2Health News:Best Drug Rehabilitation Launches New Success Stories Section of Website 2Health News:Couple Sues Over Alleged Cancer Risk Associated with use of a Power Morcellator During the Woman's Laparoscopic Fibroid Removal Procedure, Parker Waichman Comments 2Health News:Couple Sues Over Alleged Cancer Risk Associated with use of a Power Morcellator During the Woman's Laparoscopic Fibroid Removal Procedure, Parker Waichman Comments 3Health News:Couple Sues Over Alleged Cancer Risk Associated with use of a Power Morcellator During the Woman's Laparoscopic Fibroid Removal Procedure, Parker Waichman Comments 4Health News:Couple Sues Over Alleged Cancer Risk Associated with use of a Power Morcellator During the Woman's Laparoscopic Fibroid Removal Procedure, Parker Waichman Comments 5
... In ... Dr. Abdul Rao , Chief Executive Officer and Chief Research Officer, the Institute ... cross-enterprise electronic platform for timely integration of patient-specific healthcare information. , ... (Vocus) December 14, 2009 -- In ...
... than white women to receive radiation therapy after a lumpectomy, ... to a new study by researchers at The University of ... its kind and the first to examine such racial disparities ... Cancer . It was first presented at the 2008 American ...
... technology could lead to quicker detection and treatment, study ... "nanosensors" can detect early signs of cancer in everyday ... sensors hunted for and picked up biomarkers for prostate ... of the Yale Institute for Nanoscience and Quantum Engineering ...
... SAN ANTONIO - In a large review of breast ... of Texas M. D. Anderson Cancer Center have identified ... long-associated with a favorable prognosis and multiple tumors undetected ... at the CTRC-AACR San Antonio Breast Cancer Symposium, is ...
... ... Treatment Program , ... (PRWEB) December 12, 2009 -- Eighteen year addiction ends at Narconon California Drug Treatment ... prescription drugs for the last eighteen years! Imagine finding that out just before Christmas. ...
... , MEXICO CITY, Dec. 11 Genomma Lab ... its,2010 earnings guidance. , Genomma Lab expects net ... of 2010, excluding possible acquisitions, and an EBITDA margin,between 25.0% and 26.0%, ... guidance. , The Company,s estimates are based on ...
Cached Medicine News:Health News:IWHNA CEO Abdul Rao Encourages the Use of Google Health for Establishing a Patient-Specific Comprehensive Digital Health Record Across Enterprises 2Health News:IWHNA CEO Abdul Rao Encourages the Use of Google Health for Establishing a Patient-Specific Comprehensive Digital Health Record Across Enterprises 3Health News:IWHNA CEO Abdul Rao Encourages the Use of Google Health for Establishing a Patient-Specific Comprehensive Digital Health Record Across Enterprises 4Health News:Study finds racial disparities exist in radiation therapy rates for early stage breast cancer 2Health News:Study finds racial disparities exist in radiation therapy rates for early stage breast cancer 3Health News:'Nanosensors' Spot Early Signs of Cancer 2Health News:M. D. Anderson study questions true favorability of rare breast cancer type 2Health News:Nurse Celebrates Son's Drug Addiction Recovery During Holidays 2
With the Symphony family of Pacemakers, Ela presents the most advanced technology on the market. Symphony, lighter than a passport, will take your patients further, offering fast follow-up, using new...
Gentle curve facilitates less traumatic removal from eye. Increased length ideal for myopic eyes...
Sleeve extends 3mm beyond end, .90mm (20G) probe, 1.4mm (17G) sleeve...
Ideal for short scleral tunnel and trabecular meshwork incisions...
Medicine Products: